0000899243-20-021756.txt : 20200807
0000899243-20-021756.hdr.sgml : 20200807
20200807160912
ACCESSION NUMBER: 0000899243-20-021756
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200805
FILED AS OF DATE: 20200807
DATE AS OF CHANGE: 20200807
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fink Eric
CENTRAL INDEX KEY: 0001784038
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 201085295
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BLVD., SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-05
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001784038
Fink Eric
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Human Resources Officer
Common Stock
2020-08-05
4
S
0
1504
69.3185
D
950
D
Common Stock
2020-08-05
4
S
0
950
70.1008
D
0
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2020.
Represents the weighted average sale price of the shares sold ranging from $68.855 to $69.75 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents the weighted average sale price of the shares sold ranging from $69.98 to $70.30 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/Tricia Suvari, as Attorney-in-Fact
2020-08-07